House Oversight Committee criticizes drugmaker stock buybacks; says Medicare should have negotiating power

The House Oversight Committee released a report this week criticizing drugmakers' stock buybacks, finding that 14 large pharmaceutical companies spent roughly $577 billion on such buybacks and dividends from 2016 to 2020.

Read the full post at News Feed
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive